You are about to leave the website of Otsuka Novel Products GmbH and view the content of an external website. Otsuka Novel Products GmbH cannot be held responsible for the content of external websites.
Source: World Health Organization. Global Tuberculosis Report 2016. World Health Organization, Geneva, 2016.
Photo credit: Qilai Shen
Photo credit: Sergey Golovach
Photo credit: Riccardo Venturi
Sources: Brigden et al. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect Drug Resist. 2015; 8: 367–378.
Photo credit: Edwin Tuyay
The White House. Office of the Press Secretary. FACT SHEET: Obama Administration Releases National Action Plan for Combating Multidrug-Resistant Tuberculosis. December 22 2015; Available at: https://www.whitehouse.gov/the-press-office/2015/12/22/fact-sheet-obama-administration-releases-national-action-plan-combating
The Review on Antimicrobial Resistance (AMR) Chaired by Jim O’Neill. May 2016. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Available at: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf
Source: Based on Treatment Action Group, Reports on Tuberculosis Research Funding Trends, issues from 2009 until 2016 (Accessed 6 June 2017). All reports available at: http://www.treatmentactiongroup.org/tbrd
Tuberculosis (TB) is one of the oldest and most persistent epidemics, still affecting people in every country in the world. The World Health Organization estimates that in 2015, 10.4 million people became newly infected with TB, including 1 million children.1
TB is spread through air. It most commonly affects the lungs, but can spread to almost any part of the body. An estimated 1/3rd of the world population is latently infected with Mycobacterium tuberculosis, the bacteria that cause the disease. Those infected have a 10% chance of developing active TB. People with weakened immune systems, such as people living with HIV or diabetes, or people who smoke tobacco, have a much higher risk of falling ill with TB.2
Read stories of people from around the world who have successfully fought TB
The global progress in eliminating TB has been very slow, with incidence declining at only 1.5% from 2014-2015, far slower than the global target.1 TB is still one of the leading causes of death worldwide.2 In 2015 alone an estimated 1.8 million people died from this infectious disease.1
Yet with proper management, TB is curable. However, even treatment of uncomplicated forms of TB requires taking a number of medicines every day for 6 months.2
The progress in eliminating TB and curing those affected by it has been eroded by the spread of drug-resistant bacteria. To learn more about drug-resistance, click here.
Click to see slideshow and learn more about TB.
Otsuka has been searching for new tools to fight TB for over 40 years, and has been the #1 private sector funder of TB R&D in the world since 2006.3 It is committed to finding innovative solutions to effectively treat drug-resistant forms of TB, as well as to simplify and shorten treatment.
1. World Health Organization. Global Tuberculosis Report 2016. World Health Organization, Geneva, 2016. 2. World Health Organization. Tuberculosis Factsheet 104. Reviewed March 2017. Available at: http://www.who.int/mediacentre/factsheets/fs104/en/ (Accessed 8 June 2017). 3. Based on Treatment Action Group, Reports on Tuberculosis Research Funding Trends, issues from 2009 until 2016 (Accessed 6 June 2017). All reports available at: http://www.treatmentactiongroup.org/tbrd
Information current as of 26-06-2017